Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual reality buffet reveals how weight loss drugs alter food selections

NCT ID NCT06843512

Knowledge-focused Sponsor: Penn State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how GLP-1 medications (like Ozempic or Wegovy) affect people's attitudes toward food and what they choose to eat. Researchers will use a virtual reality buffet to measure food selections before starting the medication and again after three months. The goal is to understand changes in food preferences and nutrient balance in 25 adults with overweight or obesity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 medication
What this could lead to
If successful, this could help doctors understand how GLP-1 drugs change food choices, potentially leading to better nutritional guidance for people taking these medications.
What could go wrong
This is a small, early observational study with only 25 participants, so results may not apply to everyone. It does not test the drug's effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be identified from a list of medical patients prescribed GLP-1 medication by their physicians (located in offices near State College or Hershey, PA) and who volunteered to be contacted regarding studies they are eligible for.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (18+) with overweight or obesity (BMI \>25 kg/m2) * Not currently taking an incretin-based medication at baseline * Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia) * Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Fluent in English Exclusion Criteria: * Adults (18+) without overweight or obesity * \<18 years of age at time of testing * Adults not taking a GLP-1 Medication * Adults taking a compound GLP-1 * Adults on GLP-1 medication for longer than 2 weeks at baseline * Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Not fluent in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Food selection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Food Preferences obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Food selection Weight loss

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University

    RECRUITING

    State College, Pennsylvania, 16802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.